<DOC>
	<DOCNO>NCT01745120</DOCNO>
	<brief_summary>This non-randomized , open label , multi-site , single-dose , Phase 1/2 study 18 subject ( include least 3 adolescent 12 17 year age , inclusive ) beta-thalassemia major . The study evaluate safety efficacy autologous hematopoietic stem cell transplantation ( HSCT ) use LentiGlobin® BB305 Drug Product [ autologous CD34+ hematopoietic stem cell transduce LentiGlobin® BB305 Lentiviral Vector encode human β-A ( T87Q ) -globin gene ] .</brief_summary>
	<brief_title>A Study Evaluating Safety Efficacy LentiGlobin® BB305 Drug Product Beta-Thalassemia Major Subjects</brief_title>
	<detailed_description>Subject participation study 2 year . Subjects enroll study ask participate subsequent long-term follow study monitor safety efficacy treatment receive 13 year post-transplant .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Inclusion criterion : Subjects 12 35 year age , inclusive , time consent/assent , able provide write consent/assent , applicable . Diagnosis βthalassemia major history least 100 mL/kg/year pRBCs ≥8 transfusion pRBCs per year prior 2 year . Eligible allogeneic bone marrow transplant . Treated follow least past 2 year specialize center maintain detailed medical record , include transfusion history . Exclusion criterion : Positive presence human immunodeficiency virus type 1 2 ( HIV 1 HIV 2 ) . A white blood cell ( WBC ) count &lt; 3 × 109/L , / platelet count &lt; 100 × 109/L due hypersplenism . Uncorrected bleed disorder . Any prior current malignancy myeloproliferative immunodeficiency disorder . Immediate family member know suspected Familial Cancer Syndrome ( include limit hereditary breast ovarian cancer syndrome , hereditary nonpolyposis colorectal cancer syndrome familial adenomatous polyposis ) . Receipt allogeneic transplant . Advanced liver disease , include persistent aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , total bilirubin value &gt; 3 × upper limit normal , liver biopsy demonstrate cirrhosis , extensive bridging fibrosis , active hepatitis . Kidney disease calculate creatinine clearance &lt; 30 % normal value . Uncontrolled seizure disorder . Diffusion capacity carbon monoxide ( DLco ) &lt; 50 % predict ( correct hemoglobin ) . A cardiac T2* &lt; 10 m magnetic resonance imaging ( MRI ) . Any evidence severe iron overload , Investigator 's opinion , warrant exclusion . Clinically significant pulmonary hypertension , define requirement ongoing pharmacologic treatment consistent intermittent use supplemental home oxygen . Participation another clinical study investigational drug within 30 day Screening . Any prior current malignancy myeloproliferative disorder . Prior receipt gene therapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>gene therapy</keyword>
	<keyword>beta thalassemia</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>anemia</keyword>
	<keyword>CD34</keyword>
</DOC>